| Ben Zhao,Lu Wang,Qianqian Yu,Guangyuan Hu,Hong Qiu,Mingsheng Zhang,Li Sun,Ping Peng,Xianglin Yuan. Outcomes of palliative local treatment in metastatic colorectal cancer patients receiving chemotherapy plus bevacizumab. Oncol Transl Med, 2018, 4: 93-100. |
| Outcomes of palliative local treatment in metastatic colorectal cancer patients receiving chemotherapy plus bevacizumab |
| Received:April 19, 2018 Revised:June 26, 2018 |
| View Full Text View/Add Comment Download reader |
| KeyWord:metastatic colorectal cancer; palliative local treatment; bevacizumab; chemotherapy; overall survival |
| Author Name | Affiliation | E-mail | | Ben Zhao | Department of Oncology,Tongji Hospital,Huazhong University of Science and Technology | zhaoben0609@163.com | | Lu Wang | Department of Oncology,Tongji Hospital,Huazhong University of Science and Technology | | | Qianqian Yu | Department of Oncology,Tongji Hospital,Huazhong University of Science and Technology | | | Guangyuan Hu | Department of Oncology,Tongji Hospital,Huazhong University of Science and Technology | | | Hong Qiu | Department of Oncology,Tongji Hospital,Huazhong University of Science and Technology | | | Mingsheng Zhang | Department of Oncology,Tongji Hospital,Huazhong University of Science and Technology | | | Li Sun | Department of Oncology,Tongji Hospital,Huazhong University of Science and Technology | | | Ping Peng | Department of Oncology,Tongji Hospital,Huazhong University of Science and Technology | | | Xianglin Yuan | Department of Oncology,Tongji Hospital,Huazhong University of Science and Technology | xlyuan1020@163.com |
|
| Hits: 6412 |
| Download times: 7534 |
| Abstract: |
| Objective The aim of this study was to assess the value of palliative local treatment of incurable
metastatic lesions in colorectal cancer (CRC) patients receiving chemotherapy plus bevacizumab.
Methods Data of 105 patients with histologically confirmed synchronous or metachronous metastatic
CRC who received bevacizumab treatment from January 1, 2011 to January 31, 2017 were retrospectively
reviewed. Sixteen (15%) patients who were treated with bevacizumab for less than 4 cycles were excluded,
and finally, 89 (85%) patients were enrolled. Among them, 33 (37%) patients who received palliative local
treatment were categorized into the palliative local treatment group, and the remaining 56 (63%) patients
were categorized into the chemotherapy plus bevacizumab group. The primary endpoint was overall survival
(OS), which was calculated using Kaplan-Meier survival analyses. Factors possibly influencing survival
were evaluated by univariate and multivariate analyses. Adverse events (AEs) were graded according to
Common Terminology Criteria for Adverse Events, version 4.0. Grades 1–2 and 3–4 AEs of the two groups
were compared and analyzed using the Fisher’s exact test and χ2 analysis.
Results The median follow-up period was 20.4 months, ranging from 1 to 60 months. The median OS
in the palliative local treatment group was 36.3 months (95% CI, 33.5–39.2), and that in the chemotherapy
plus bevacizumab group was 20.5 months (95% CI, 17.6–23.4). Both the univariate (HR 0.13, 95% CI,
0.05–0.30, P < 0.001) and multivariate (HR 0.16, 95% CI, 0.07–0.39, P < 0.001) analyses showed that the
addition of palliative local treatment could prolong survival compared with chemotherapy plus bevacizumab
alone. There were no significant differences in the rates of common chemotherapy- or bevacizumab-related
AEs between the two groups.
Conclusion These findings suggest palliative local treatment is an effective and safe method for treating
patients with incurable metastatic CRC receiving chemotherapy plus bevacizumab. |
| Close |
|
|
|